Bionomics (ASX:BNO) exercises underwriter’s option in US

• Bionomics Limited (BNO) announces the issuance of 243,300 American Depositary Shares (ADSs), to exercise the option connected with a previously announced IPO
• The ADSs each represent 180 ordinary shares of Bionomics and were sold at a public offering price of US$12.35 per ADS
• The total gross proceeds, including the previously issued 1.62 million ADSs, increased to approximately US$23 million
• This is before deducting underwriting discounts and commissions and other offering expenses payable by Bionomics
• Bionomics Limited (BNO) last traded at $0.11 per share before market open on January 6

Bionomics (BNO) announces the issuance of 243,300 American Depositary Shares (ADSs), to exercise the option connected with a previously announced IPO in the United States.

The ADSs each represent 180 ordinary shares of Bionomics and were sold at a public offering price of US$12.35 (A$17.11) per ADS.

The total gross proceeds, including the previously issued 1.62 million ADSs, increased to approximately US$23 million (A$31.8 million).

This is before deducting underwriting discounts and commissions and other offering expenses payable by Bionomics.

The ADSs began trading on the Nasdaq Global Market on December 16, under the ticker symbol ‘BNOX’.

Evercore ISI and William Blair acted as lead book-running managers for the offering.

Cantor, Berenberg and H.C. Wainwright & Co. acted as book-running managers for the offering.

Bionomics is advancing its lead product candidate, BNC210, for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder.

BNC210 is in its Phase 2b trial, known as the ATTUNE Study.

The study will evaluate a tablet formulation of the candidate to be used as a treatment for the previously mentioned disorders.

Bionomics (BNO) last traded at $0.11 per share before market open on January 6.